Actinium Pharmaceuticals is
a public biopharmaceutical company specializing in the development of cancer
drugs. The company’s product candidates are based on its patented technology,
co-developed with Memorial Sloan Kettering Cancer Center (MSKCC), for combining
the cancer targeting precision of monoclonal antibodies (mAb) for targeting
specific types of cells with the power of alpha emitting radioisotopes, the
most potent cancer killing agents in existence.
Currently, Laidlaw &
Company is initiating coverage on ATNM, with a buy rating and a price target of
$18.00. It is believed that ATNM’s technology platform using the cancer-cell
killing ability of alpha and beta-emitting isotopes will produce novel drugs
that will ultimately become viable oncology treatments. Among its current
projects:
* Iomab-B, a combination of
a monoclonal antibody and a beta-emitting radioisotope, is being developed for
patients in need of a hematopoietic stem cell transplantation (HSCT) and is potentially
entering Phase III in 2014, after showing impressive Phase I/II data.
* Actimab-A is an innovative
treatment for acute myeloid leukemia (AML), and is a radioimmunoconjugate
consisting of a monoclonal antibody and the isotope actinium-225. Phase I data
showed elimination of leukemia calls from blood in 67% of all evaluable
patients who received a full dose. The Phase II portion of this trial to
complete in mid-2014 and Actimab-A could possibly be launched by the end of
2019, potentially addressing a global AML market of $1 billion.
* Broad Applications
Possible for Several Cancer Types. Actinium has technology to attach
radioisotopes to monoclonal antibodies. The company aims to use this platform
to develop in-licensed monoclonal antibodies to target several cancer types and
it has a strategy to improve on marketed oncology products by adding
alpha-emitting isotopes.
ATNM has an expert team of
professionals, possessing the vision and desire to enhance shareholder value
and position the company to benefit from increased market recognition of
targeted payload therapies and an initial high-value, niche product model. For more
information about the company and what it can offer investors, visit
www.actiniumpharmaceuticals.com.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
